Melanotan II is the cyclic, non-selective member of the melanotan pair — developed in the same University of Arizona lab as MT-I (afamelanotide) but with a radically different fate. Where MT-I is a single-purpose key selective for the MC1R skin-pigmentation receptor, MT-II is a master key that activates four of five melanocortin receptors indiscriminately — including brain receptors that control appetite and sexual arousal. The appetite suppression and erectile effects that made MT-II popular are not features; they are pharmacological proof of non-selective CNS receptor activation.

What MT-II Is

In 1989, Al-Obeidi, Hadley, and Hruby truncated alpha-MSH to its minimal active core (the His-Phe-Arg-Trp tetrapeptide) and cyclized it with a lactam bridge between aspartic acid and lysine, producing a cyclic heptapeptide (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2). The cyclization increased enzymatic stability but eliminated receptor selectivity, creating an agonist that binds MC1R, MC3R, MC4R, and MC5R with sub-nanomolar to low-nanomolar affinity. Its cyclic structure confers enough lipophilicity to cross the blood-brain barrier, enabling direct activation of hypothalamic MC4R — the receptor mediating appetite regulation and sexual arousal. Like MT-I, it does not activate MC2R, so it doesn't trigger cortisol synthesis.

Pharmacokinetics

MT-II is rapidly absorbed after subcutaneous injection. The nasal-spray route popularized on social media has substantially lower and more variable bioavailability — no published clinical trial has used the intranasal route, and no quantitative nasal-vs-subcutaneous PK comparison exists.

Receptor Pharmacology — Why Non-Selectivity Is the Liability

MT-II activates MC1R (melanogenesis and DNA repair), MC3R/MC4R (central appetite suppression and sexual arousal — relevant because it crosses the BBB), and MC5R (exocrine effects of uncertain significance). The tanning effect attracted consumer demand, but the concurrent MC4R-mediated erectile, appetite, and CNS effects — plus MC3R/MC5R activity of uncertain long-term significance — created a side-effect profile incompatible with any single therapeutic indication.

Clinical Evidence — Thin

MT-II's only formal trial is Dorr et al. (1996): a single-blind, placebo-controlled Phase I in three male volunteers (0.01–0.025 mg/kg SC), showing dose-dependent tanning, nausea, and — unexpectedly — spontaneous erections. That serendipitous MC4R discovery redirected development toward bremelanotide (PT-141), FDA-approved in 2019 as Vyleesi. Erectile data (Wessells, n=10–20) are pharmacologically notable: 8 of 10 men with psychogenic ED developed clinical erections, with mean tip rigidity >80% for 38 minutes vs 3 minutes on placebo. The Dorr effective tanning doses (0.7–1.75 mg) are 2–3× higher than current community loading protocols (250–500 mcg), which reflect a nausea-minimization trade-off rather than an evidence-based threshold. MT-II's anorectic effect undergoes tachyphylaxis with chronic use; no Phase III trial has ever been conducted for MT-II in any indication.

Safety and Serious Adverse Events

Nausea is the most common adverse event (13% severe at the erectile dose). The documented dermatologic signal is nevi changes: darkening of existing moles, eruption of new (including dysplastic) nevi, and melanonychia. Case reports of unregulated use document rhabdomyolysis (a 39-year-old who injected 6 mg, CPK peaking at 17,773 IU/L, three days of intensive care), renal infarction (~27 mg cumulative over 6 months, ~50% of one kidney), and priapism. These occurred at doses far exceeding typical protocols, but the absence of dosing guidance, quality assurance, or medical oversight makes such outcomes structurally predictable. On the melanoma question, all five published melanoma cases in MT-II users involved confounding factors (tanning-bed use, fair skin, familial melanoma risk) — most plausibly attributed to UV damage in a self-selected sun-seeking population rather than MC1R activation itself.

The Gray Market and Product Quality Problem

MT-II is illegal to sell in the US, UK, and Australia (FDA Category 2 since 2023, barred from compounding), though not DEA-scheduled. It circulates widely via gray-market channels — online peptide ads surged 208% in 2024. The most underappreciated risk is manufacturing-related: when Imperial College London analyzed 10 commercial tanning kits, some contained more than 100 unidentified ingredients; LegitScript data show 68% of tanning-peptide adverse-event reports involved unlicensed vendors and 41% of tested products showed contamination or mislabelling. Users cannot meaningfully assess their exposure. A 2022 shift driven by TikTok nasal-tanning-spray content (including flavored sprays — peach, bubblegum, grape) has raised youth-targeting alarms, with the UK CTSI drawing parallels to the disposable-vape epidemic. MT-II is expected to remain restricted even after the February 2026 HHS partial reversal of Category 2 peptide bans, given its cardiovascular risk profile and melanoma signal.